BB-1701
- Generic Name
- BB-1701
- Drug Type
- Biotech
- Background
BB-1701 is a humanized IgG1 kappa monoclonal antibody (anti-HER2 antibody) conjugated to eribulin developed by Bliss Biopharmaceutical.
ANGLE's Parsortix System Shows Promise in Real-Time HER2 Status Monitoring for Breast Cancer Patients
• ANGLE plc has successfully completed development of two assays for AstraZeneca: an Androgen Receptor assay for prostate cancer and a DNA damage response micronuclei assay, positioning the company for large-scale clinical trials.
• Results from Eisai's Phase 2 pilot study demonstrate that ANGLE's Parsortix-based HER2 assay can effectively measure changes in breast cancer patients' HER2 status over time, offering advantages over traditional tissue biopsies.
• The liquid biopsy technology shows potential to identify patients who may benefit from HER2-targeted therapies despite initially testing negative via tissue biopsy, potentially expanding treatment options and improving patient outcomes.
Robust Clinical Trial Pipeline Fuels Hope for Renal and Breast Cancer Advances
• The renal cancer clinical trial pipeline is robust, with over 70 companies developing more than 75 therapies, including novel immunotherapies and targeted agents.
• Breast cancer research is also thriving, with over 100 companies exploring 120+ new drugs, such as antibody-drug conjugates and PARP inhibitors, in clinical trials.
• Recent FDA actions, including Fast Track and Breakthrough Therapy designations, highlight the potential of emerging therapies for both renal and breast cancer.
• Advances in diagnostics, such as PET imaging agents for clear cell renal cell carcinoma, are also contributing to improved management of these diseases.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath